Schrodinger, Inc. (SDGR)
| Market Cap | 3.92B |
| Revenue (ttm) | 120.74M |
| Net Income (ttm) | -41.96M |
| Shares Out | 70.58M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 397,228 |
| Open | 55.75 |
| Previous Close | 55.01 |
| Day's Range | 54.37 - 55.75 |
| 52-Week Range | 47.59 - 117.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 87.60 (+58.2%) |
| Est. Earnings Date | Nov 11, 2021 |
About SDGR
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharma...
Financial Performance
In 2020, Schrodinger's revenue was $108.10 million, an increase of 26.36% compared to the previous year's $85.54 million. Losses were -$24.46 million, -0.44% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 87.60, which is an increase of 58.24% from the latest price.
News
MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program
HOUSTON & NEW YORK--(BUSINESS WIRE)--MD Anderson and Schrödinger today announced a strategic research collaboration to accelerate the development of Schrödinger's WEE1 Inhibitor Program.
This Healthcare Company Is Using AI to Develop Drugs
Could this technology be the future of the pharmaceutical industry?
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
One Stock to Dominate Biotech
The amazing biotech advancements coming this decade… breakthroughs in drug discovery… the unrivaled leader in the space from Luke Lango… how it becomes a 10X winner In early January 2020, the Harvard ...
Schrödinger to Present at Four Investor Conferences in September
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at four investor conferences in September.
Why Schrödinger Shares Are Rising
Schrödinger Inc (NASDAQ: SDGR) shares are trading higher by 4.8% at $62.58 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and announced an $82 price target. Schrödinger shares w...
4 Specialized AI Stocks to Buy for the Boom
Companies with focused AI technologies appear to be doing better than firms with AI based on general data. Here are four AI stocks to buy.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
Schrödinger Stock Is Trading Lower After Reporting Deeper Than Expected Q2 Loss
Schrödinger Inc (NASDAQ: SDGR) has reported Q2 revenues of $29.78 million, +29% Y/Y, slightly missing the consensus of $29.88 million. Software revenue was $24.1 million, +15%.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -68.97% and -1.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Schrodinger Q2 Earnings
Shares of Schrodinger (NASDAQ:SDGR) decreased 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 880.00% over the past year to ($0.49), whic...
Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the second quarter of 2021 and provided a company update.
Is a Surprise Coming for Schrodinger (SDGR) This Earnings Season?
Schrodinger (SDGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Mid-Cap Stocks to Buy Ahead of Earnings Results This week
The four mid-cap stocks discussed here are slated to release earnings results this week. These are CACI, SDGR, AVT and GRWG.
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Schrodinger, Inc. (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
NEW YORK & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)--Schrödinger and Zai Lab today announced a global R&D collaboration in oncology.
Schrödinger to Host Conference Call to Discuss Second Quarter 2021 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report second quarter 2021 financial results on August 12, 2021.
Schrodinger (SDGR) Sees Hammer Chart Pattern: Time to Buy?
Schrodinger (SDGR) has been struggling lately, but the selling pressure may be coming to an end soon.
Schrödinger Hosts First Annual Educator's Day and Announces “Teaching with Schrödinger” Program
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will host its first annual Educator's Day and "Teaching with Schrödinger" Program.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
Schrödinger to Present at Two Virtual Investor Conferences in July
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at two investor conferences in July.
My Favorite Biotech Stock Right Now
I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
